NGM Biopharmaceuticals Inc NGM:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:45 PM EDT
28.00quote price arrow up+0.08 (+0.29%)
Volume
2,208
Close
27.92quote price arrow up+0.80 (+2.95%)
Volume
201,764
52 week range
14.93 - 32.12

...

Loading . . .
  • Open27.11
  • Day High28.50
  • Day Low26.80
  • Prev Close27.12
  • 52 Week High32.12
  • 52 Week High Date03/17/21
  • 52 Week Low14.93
  • 52 Week Low Date09/24/20

Key Stats

  • Market Cap2.15B
  • Shares Out77.02M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta1.93
  • YTD % Change-7.84

KEY STATS

  • Open27.11
  • Day High28.50
  • Day Low26.80
  • Prev Close27.12
  • 52 Week High32.12
  • 52 Week High Date03/17/21
  • 52 Week Low14.93
  • 52 Week Low Date09/24/20
  • Market Cap2.15B
  • Shares Out77.02M
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta1.93
  • YTD % Change-7.84

RATIOS/PROFITABILITY

  • EPS (TTM)-1.57
  • P/E (TTM)-17.75
  • Fwd P/E (NTM)-15.71
  • EBITDA (MRQ)-104.537M
  • ROE (MRQ)-30.87%
  • Revenue (MRQ)84.58M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-131.14%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NGM Biopharmaceuticals Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company’s product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively...
William Rieflin J.D.
Chairman
David Woodhouse Ph.D.
Chief Executive Officer
Siobhan Mangini
Chief Financial Officer
Address
333 Oyster Point Blvd
South San Francisco, CA
94080-1978
United States

Top Peers

SYMBOLLASTCHG%CHG
RCUS
Arcus Biosciences Inc
29.15+0.42+1.46%
DCPH
Deciphera Pharmaceuticals Inc
33.01-0.52-1.55%
EDIT
Editas Medicine Inc
31.72-1.08-3.29%
MGNX
MacroGenics Inc
28.94-1.61-5.27%
SRNE
Sorrento Therapeutics Inc
6.58-0.40-5.73%